Metabolic & GLP-1

SLU-PP-332

SLU-PP-332 is a synthetic small molecule designed to activate estrogen-related receptors, triggering a genetic program in muscle cells that resembles some effects of aerobic exercise. It is studied as an exercise mimetic, but no human trials have been conducted.

Classification
Pan-ERR agonist (synthetic small molecule)
Half-Life
Not well established in published data
Format
Capsule

What Is SLU-PP-332?

SLU-PP-332 is a synthetic compound developed to activate ERRα, ERRβ, and ERRγ, a family of proteins involved in energy metabolism and mitochondrial biogenesis. ERRα sits in a regulatory loop with PGC-1α, a driver of the cell's response to exercise, which made the pathway attractive for researchers studying exercise-related biology.

A 2017 expert perspective cautioned that exercise mimetic compounds may have a credible mechanistic basis in animal biology without producing effects that translate to humans. SLU-PP-332 has not entered human clinical trials.

What SLU-PP-332 Is Being Researched For

  • Exercise Endurance and Muscle Fiber Composition

    The foundational study found activation of an acute aerobic exercise genetic program in mouse skeletal muscle, increased type IIa oxidative muscle fibers, and enhanced exercise endurance.[1]

  • Metabolic Syndrome and Obesity

    A follow-up study in obese mice found increased energy expenditure and fatty acid oxidation alongside decreased fat mass accumulation.[2]

  • Cardiac Metabolism

    More recent research has extended the mechanism into heart failure models, where pan-ERR agonism enhanced cardiac fatty acid metabolism and mitochondrial function.

How SLU-PP-332 Works

  • Activating the ERR-PGC-1α Regulatory Loop

    Research points to SLU-PP-332 activating all three ERRs, which sit in a regulatory loop with PGC-1α. This turns on genes involved in mitochondrial biogenesis and fatty acid oxidation.[1]

  • Inducing an Aerobic Exercise Gene Program

    Research points to SLU-PP-332 inducing DDIT4, a protein normally induced after aerobic exercise that triggers a broader genetic program of exercise-related adaptations.[1]

  • A Different Mechanism Than Mitochondrial Uncouplers

    SLU-PP-332 works as a nuclear receptor agonist that drives gene transcription, unlike mitochondrial uncouplers such as BAM15, which act directly on the mitochondrial membrane.

Reconstitution and Handling

SLU-PP-332 is typically supplied in capsule form for oral research use. Capsules should be stored in a cool, dry place away from direct light and handled according to the specific product's labeling since formulations can vary by supplier.

Key Takeaways

SLU-PP-332 has a coherent mechanistic basis in ERR biology, and animal data spans muscle endurance, metabolic disease, and cardiac function. It remains entirely preclinical, and expert commentary cautions against assuming that mechanistic plausibility in rodents will translate into meaningful human effects.

Frequently Asked Questions

What is SLU-PP-332 derived from?

It's a fully synthetic small molecule designed specifically to activate the estrogen-related receptor family.

Does SLU-PP-332 substitute for exercise?

No. Exercise produces coordinated effects across many body systems, while this compound activates one genetic pathway. The exercise-mimetic label should not be treated as proof of substitution.

What has SLU-PP-332 been studied for?

Research spans exercise endurance and muscle fiber composition, metabolic syndrome and obesity, and cardiac metabolism in animal and cell models.

Has SLU-PP-332 been tested in humans?

No. No human clinical trials have been registered or conducted for this compound.

Is there a successor compound?

Yes. SLU-915, also called SLU-PP-915, was developed with improved oral bioavailability and has likewise only been studied preclinically.

Sources and Research

  1. Billon C, et al. A Synthetic ERRα Agonist Induces an Acute Aerobic Exercise Response and Enhances Exercise Capacity. bioRxiv. 2022; subsequently published in a peer-reviewed journal.
  2. Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Mol Metab. 2024.

Related Reading

For educational and research purposes only. Not medical advice. Always consult a licensed healthcare professional before starting any protocol.